Kuros Biosciences Ltd. — Earnings Release 2010

Apr 22, 2010

News Details

Corporate | 22 April 2010 06:45

Cytos Biotechnology Ltd First Quarter Report 2010

Cytos Biotechnology AG / Quarter Results

22.04.2010 06:45

Dissemination of a Corporate News, transmitted by
DGAP - a company of EquityStory AG.
The issuer / publisher is solely responsible for the content of this announcement.

---

Cytos Biotechnology Ltd First Quarter Report 2010 as of March 31, 2010

Summary of important events in Q1 2010

• Partner Novartis starts a further placebo-controlled phase II study
  with the vaccine candidate CAD106 in 120 Alzheimer's disease patients

• Change of Chairmanship in the Board of Directors

• Jakob Schlapbach (59) will resign as CFO during the year 2010 and will
  be proposed to become a member of the Board of Directors

• Upcoming events:

  • Presentation at the Vaccine Innovation, April 28-29, 2010 in
    Frankfurt, Germany

  • Presentation at the EAACI London 2010, June 5-9, 2010 in London, UK

  • Presentation at the Active Immunotherapeutics Forum, June 21-23,
    2010 in Barcelona, Spain

• Financial summary

in CHF million Q1 2010 Q1 2009
Revenue 0.3 0.3
Net operating costs (6.9) (11.0)
Net loss (3.8) (11.8)
03/31/10 12/31/09
Cash, cash equivalents, 47.9 60.5
financial assets and
trade receivables
Full-time employees (number) 82 85

The complete First Quarter Report can be downloaded on Cytos
Biotechnology's website under the following link:

http://www.cytos.com/userfiles/file/Cytos_Q1_2010_E.pdf

Jakob Schlapbach, MBA
Chief Financial Officer
Cytos Biotechnology Ltd
Phone: +41 44 733 46 46
Fax: +41 44 733 47 02
e-Mail: jakob.schlapbach@cytos.com
Website: www.cytos.com

22.04.2010 Ad hoc announcement, Financial News and Media Release distributed by DGAP.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: Cytos Biotechnology AG
Wagistr. 25
8952 Schlieren
Schweiz
Phone: +41 44 733 4747
Fax: +41 44 733 4740
E-mail: info@cytos.com
Internet: www.cytos.com
ISIN: CH0011025217, CH0029060735
WKN: -
Listed: Freiverkehr in Berlin, München, Stuttgart; Open Market in
Frankfurt; Foreign Exchange(s) SIX

End of News DGAP News-Service

---